[[null, "<p>\u6b22\u8fce\u4f7f\u7528 \u5f20\u5e73\u7684\u4e13\u5c5e\u77e5\u8bc6\u5e93\uff01</p></p>\n<p>\u8bf7\u5728\u53f3\u4fa7\u5207\u6362\u6a21\u5f0f\uff0c\u76ee\u524d\u652f\u6301\u76f4\u63a5\u4e0e LLM \u6a21\u578b\u5bf9\u8bdd\u6216\u57fa\u4e8e\u672c\u5730\u77e5\u8bc6\u5e93\u95ee\u7b54\u3002\n\u77e5\u8bc6\u5e93\u95ee\u7b54\u6a21\u5f0f\uff0c\u9009\u62e9\u77e5\u8bc6\u5e93\u540d\u79f0\u540e\uff0c\u5373\u53ef\u5f00\u59cb\u95ee\u7b54\uff0c\u5982\u6709\u9700\u8981\u53ef\u4ee5\u4e0a\u4f20\u6587\u4ef6/\u6587\u4ef6\u5939\u81f3\u77e5\u8bc6\u5e93\u3002\n\u77e5\u8bc6\u5e93\u6682\u4e0d\u652f\u6301\u6587\u4ef6\u5220\u9664\u3002"], [null, "\u6a21\u578b\u5df2\u6210\u529f\u52a0\u8f7d\uff0c\u53ef\u4ee5\u5f00\u59cb\u5bf9\u8bdd\uff0c\u6216\u4ece\u53f3\u4fa7\u9009\u62e9\u6a21\u5f0f\u540e\u5f00\u59cb\u5bf9\u8bdd"], [null, "\u5df2\u52a0\u8f7d\u77e5\u8bc6\u5e93tumor-diag\uff0c\u8bf7\u5f00\u59cb\u63d0\u95ee"], ["introduce the table of content of NCCN guidelines of colon cancer.", "\u6839\u636e\u6240\u63d0\u4f9b\u7684\u5df2\u77e5\u4fe1\u606f\uff0cNCCN \u6307\u5357\u7684\u7ed3\u80a0\u764c\u90e8\u5206\u5305\u62ec\u4ee5\u4e0b\u76ee\u5f55\uff1a\n\nI. \u539f\u5219\u4e0e\u6210\u50cf\uff08Imaging Principles\uff09\nII. \u80bf\u7624\u5206\u671f\uff08Tumor Stage\uff09\nIII. \u6cbb\u7597\u65b9\u6848\uff08Treatment Options\uff09\nIV. \u5316\u7597\u53c2\u8003\uff08Chemotherapy References\uff09\nV. \u611f\u67d3\u98ce\u9669\u4e0e\u76d1\u6d4b\uff08Infection Risk Monitoring\uff09\nVI. \u540e\u7eed\u6cbb\u7597\uff08Follow-Up Care\uff09\nVII. \u7ed3\u8bba\uff08Conclusion\uff09\n\n\u5176\u4e2d\uff0c\u5316\u7597\u53c2\u8003\u90e8\u5206\u5305\u62ec\u4e86\u4e0d\u540c\u5316\u7597\u65b9\u6848\u7684\u8be6\u7ec6\u4fe1\u606f\u3002\n\n<details> <summary>\u51fa\u5904 [1] ColonCancer_2023.V2_EN.pdf</summary>\nclinical  trial.  Participation in clinical trials is especially encouraged.  NCCN Guidelines Index Table of Contents Discussion Documented metachronous metastasesmm, nn by CT,  MRI,  and/or biopsy COL-9 b Principles of Imaging (COL-A).\n</details><details> <summary>\u51fa\u5904 [2] ColonCancer_2023.V2_EN.pdf</summary>\npatient  with  cancer  is  in  a  clinical  trial.  Participation in clinical trials is especially encouraged.   NCCN Guidelines Index Table of Contents Discussion SUBSEQUENT THERAPYc, o, p  Previous  oxaliplatin-  based  therapy  without  irinotecan  CONTINUUM  OF \n</details><details> <summary>\u51fa\u5904 [3] ColonCancer_2023.V2_EN.pdf</summary>\npatient  with  cancer  is  in  a  clinical  trial.  Participation in clinical trials is especially encouraged.   NCCN Guidelines Index Table of Contents Discussion SUBSEQUENT THERAPYc, o, p  Previous  irinotecan-  based  therapy  without  oxaliplatin  CONTINUUM  OF \n</details><details> <summary>\u51fa\u5904 [4] ColonCancer_2023.V2_EN.pdf</summary>\nis  in  a  clinical  trial.  Participation in clinical trials is especially encouraged.   NCCN Guidelines Index Table of Contents Discussion SUBSEQUENT THERAPYc, o, p CONTINUUM OF CARE - SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASEa, b, n  FOLFOXd  or \n</details><details> <summary>\u51fa\u5904 [5] ColonCancer_2023.V2_EN.pdf</summary>\nclinical  trial.  Participation in clinical trials is especially encouraged.  NCCN Guidelines Index Table of Contents Discussion a For chemotherapy references,  see Chemotherapy Regimens and References (COL-D [9 of 14]).  b For infection risk,  monitoring,\n</details>"]]